THE PRIMARY EFFICACY ENDPOINT FOR ALIROCUMAB, REDUCTIONS IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL
4CPS-030
ANALYSIS OF ADAPTATION TO A PROTOCOL OF USE OF THE PCSK9 INHIBITORS
4CPS-029
CLINICAL EXPERIENCE OF NEW LIPID-LOWERING THERAPIES: EVOLOCUMAB AND ALIROCUMAB
4CPS-028
STATIN OVERUSE? EVALUATION OF STATIN INITIATION FOR PRIMARY PREVENTION DURING HOSPITALISATION BETWEEN TWO NEIGHBOURING COUNTRIES IN EUROPE IN HIGH-RISK PATIENTS
4CPS-027
REAL-WORLD EFFECTIVENESS OF EVOLOCUMAB AND ALIROCUMAB AT 12 MONTHS OF TREATMENT
4CPS-026
ADHERENCE AND EFFECTIVENESS OF PCSK9 INHIBITORS IN ROUTINE CLINICAL PRACTICE
4CPS-025
LIPID MODIFICATION THERAPY FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
4CPS-024
EFFICACY, SAFETY AND ACCEPTANCE OF TREATMENT WITH ALIROCUMAB OR EVOLOCUMAB IN PATIENTS WITH DYSLIPIDAEMIA
4CPS-023
SACUBITRIL/VALSARTAN (ENTRESTO) IN REAL LIFE: AN OBSERVATIONAL STUDY IN A HOSPITAL CENTRE
4CPS-022
HIGH INPUT IN PATIENT SAFETY - DOCUMENTATION OF CARDIOVASCULAR SYSTEM DRUGS
4CPS-021
ABSTRACT WITHDRAWN
4CPS-020
ANTICOAGULATION THERAPY IN HAEMODIALYSIS - A CLINICAL PHARMACIST EXPERIENCE IN A PRIMARY CARE TEAM
4CPS-019
MEDICATION USE EVALUATION OF EDOXABAN IN A TERTIARY HOSPITAL
4CPS-018
EVALUATION OF ANTIPLATELET AGENT PRESCRIBING IN PATIENTS ON DIRECT ORAL ANTICOAGULANT
4CPS-017
EVALUATION OF PHARMACISTS' INPUT IN ANTICOAGULATION CLINIC REVIEWING DIRECT ORAL ANTICOAGULANTS INITIATED IN A SECONDARY CARE HOSPITAL IN LONDON
